Category Archives: Genetics

Fungal Genetics Conference Q&A identifying new L maculans effectors, a fungal pathogen of oilseed rape – BMC Blogs Network (blog)

Fungal Biology and Biotechnologyrecently attended the 29th Fungal Genetics Conference in California. Whilst there, we invited three young scientists who presented excellent posters to take part in a Q&A. In this blog we talk to Julie Gervais, a third year PhD student in INRA BIOGER (France) whos currently working on a fungal pathogen of oilseed rape, Leptosphaeria maculans.

Julie Gervais 23 Jun 2017

Leptosphaeria maculans is an oilseed rape pathogen and is responsible for the stem canker disease.

Pixabay

My name is Julie Gervais and I am a third year PhD student in INRA BIOGER (France) working on a fungal pathogen of oilseed rape, Leptosphaeria maculans, which is responsible for the stem canker disease. This fungus has two colonization stages of the plant. During the first stage, the fungus infects leaves and cotyledons (the first leaves to appear from a germinating seed). Once in the leaves, the fungus has a short biotrophic stage of 10 days and then switches to necrotrophy.

Following this primary leaf infection, L. maculans grows inside the stem tissues during a long endophytic systemic colonization. This colonization is completely symptomless and may last up to 9 months. I am aiming to gain a better understanding of how the fungus can grow inside the oilseed rape stem for several months without causing any symptoms. I am particularly focused on the identification of new effectors, secreted proteins, produced by the fungus enabling it to develop itself efficiently into the plant.

I am particularly focused on the identification of new effectors, secreted proteins, produced by the fungus enabling it to develop itself efficiently into the plant.

By transcriptomic analysis, I identified late effector candidates, under-expressed in the early colonization stage and over-expressed in the infected stems. My analysis revealed a link between the regulation of expression of effectors and their genomic location: the late effector candidates, putatively involved in systemic colonization, are located in gene-rich genomic regions, whereas the early effector genes, over-expressed in the early colonization stage, are located in gene-poor regions of the genome. These results were recently published in an article of Molecular Plant Pathology.

I am also trying to confirm the role of effector for six late effector candidates: I am measuring the impact of the silencing of these genes on the fungal growth inside the stem. Preliminary results indicated that the silencing of one of these candidates induced smaller necrosis on the stem.

Another aim of my thesis is to identify new resistances to control L. maculans. The identification of new effector genes would contribute to the identification of new resistance genes specific to these effectors.

During my studies, I became more interested in the understanding of interactions between plants and micro-organisms, so I decided to pursue this interest in my thesis on L. maculans and its host, oilseed rape. I especially enjoy trying to dissect the network of interactions between the two organisms and to be able to apply such findings in the effective control of plant diseases.

I would advise young scientists to stay focused on what they are interested in and to always take pleasure in what they do. Science is fun!

I was able to attend to the Fungal Genetics Conference thanks to travel fundings from the Acadmie dagriculture (grant Jean & Marie-Louise Dufrenoy) and from the Genetics Society of America.

Enjoyed reading this blog? Read our otherFungal Genetics Conference Q&As here:

View the latest posts on the On Biology homepage

By commenting, youre agreeing to follow our community guidelines.

See the rest here:
Fungal Genetics Conference Q&A identifying new L maculans effectors, a fungal pathogen of oilseed rape - BMC Blogs Network (blog)

Florida higher education official said women may earn less than men because of genetics – New York Daily News

Yys6?3wf1%:X./YWIH$w(^]M"B w9pyLd 3"~@X=d3*1Ob=fetub ';1,e2$HfTBZ6q7`A d1C$]bjmP|%[uM1NfO~Czg0jY+KbXVU%N)E$,RE1w^(#|W98F}Ej^Y4[gy0|~ZfX'.rk=v50#9>l$E z[o|YQTh^Vy^6N*jT)V*eVb ,,OP7E a, 'p@=S{{<^- BJwi h{dR*%%+Y&>V`f K1qL@)e)bcSYJLD`XM mLB@%@69o{HrE*K BO"0cc?KAh<[gj`=B#cgRa{LJcE>N%d`+?u1u1Bt@.(.&%RVJg55Y tz)Rq JD.Y@ue> ?u:$ 9 q]lFtL_|Q.8{GBbOM4"@0xZG(g:P/^/)kDl_1!o@B-Ig@d)/Wj" @FHM|V>x31.cy9QT_@w;(Vh=id8i8eKnZ ^4QxpwPWE~!D,*@dV.bXx|$pL7{z%M9=htbt)Nl^l{=`e9L.6O;>}EnP"`5T)JT, QvpsG=w=Y?>J9nX=A_o>.4,O% F-65oc0weGg)>XyOj'pOzC5trsrg 99 Jg9|t1lb5xieW5t'~|x |~ qQ;BHNsez6Vz'n>33bXcU?uWISv>F4]4hNB7 4Io3yI"el)Zy7W> j3l$aa}GANK0 ~LXp80s$2}30A Q I) uq#7T97d/Tg,wnE$CqP-h C us }n'EJezli:$#j9%.zkoPvXH7TzwZd(H@jTO8"+")H%uW::nZU=0"?g*@mw=M e>*z$# X75_|9o<>4s2 ETOd0sh*kv_#5v:iW=dq3o Xbd(y05uz!=^bF)L-+:on0'_;3hs/z^x=Um/@k,*tfpqu9Bp?V8mMyj'w[xpa}.iKaKmCL;2wq7lu.u:07lJ57-;v*=v7{{tloM)zy=nO2gRf7Ma8)<|;K(38ou;}IdtkS|riaZv>^d>M-`& tc?xz4}a<4>5NW5-naQoSm+e[M)yV*FdNjPW< &v:|24U[961n|r +K-pV#j:*V@dSQZAKZ [cYrH ?MDwXeS=,!,D-$.Wt#L2o{WZ59k6q)Gh,;L9#yi+rr~)qd{B'Nij5=`MN]TslA3` y Vv:|,NOqE-dOA:t}p.0cM=$%Oq!cA1/1Q^+QfgE!Yoj/L2? 3 Cf9edzyo[.0y:rgU^3/Q]2*b?YOu}1d9822/.y"/Y>$ky.g#7WQEnP=!P y`?h-hOI,R#R*[ZDsp2<4#ml8'k[W'p} UiW`>g3Y>cPMmqZ0$?f^pqG8^-BOMc9xa6o;Y|+sW'|ga=jQ:i 1?^FL;2?C+vZ'xM_W1[=W,d;/I3p/[]Gw^Bw2EA,-hHo$nX?edy.f[UYjo nP]K?vs;z?<|?/>s3;~ot{.OAuYlp"P{{ND1^1;mpsoZ L%BKQoPv{~7s 5^n4_y 9zbSY{yO^mByY~m@)vS}%U>H3|@)~8u|%R`49K>5}[x'_tZ%7ygrZosx%{5-~O<0YA97p~,n"AG7xxg%:Gccd-;yko_g2*C::yDmz]OX:vM(m3 nG1Q-Tsg4Ud9hGrD]}}i+O1|MNsz/1h$~&eY0RTIk^Qo[j,xmT*6{C_Whk?WMFuN?yMwS4ivg4:?=e9 ?FV+Zql>('}2XTi 9'9GCE>]uL.B_OB}~87jI; ngp9z~qw<;:)2ywM@s,?,W ]poOL"].=:}:[Sl6R~8PO#HlE=cra0O?m.#sF9B3OQt}}xAE<~l|3gB2~E@_@'0iydZ?GhS?);'8y,zMi ~3NKOD80?s}J(g;U"68F5|uJN-cChOZ9J8E,nVgSz6 ooBkwGW.yHi}Y3ux};Li+=H:~uc.B{?k5t*?|yE_r4p6$+tC>W;%G=dJ}0wr@<.K6g}hy]!&1|vTP8Y[X}_QoI|=^ 7Z(gMM e^{s&w***w8FRvQC_Us7GY4iUQ9 W%=U9}$f UEd&JFvs"r,(ej<CsD{%,=N`dlq4ou,]<;B}rnLj]JO<_?>wsS_,'r-' g~j>mnPbO~R'JAI{=bw83>{^&}MV'?k0]]Zlt-Vn Sk*sG/Eg2V-FVjA/jf- ;_ bc:i>G&sNMA|e@C+0jmqt?9h6umj p:(;5AT7 `Vj,&[746KH:eKTB5'/wY0SmpO$rL.uyB4>K`n{Lwa/bu< Q6IVwxiqACg~P_6k+Zo(g">y55k00,]3?tegmFYECyNw'm4sN:wc Iw6CLeK;[%|/R~]Mg]Fq Qzcn I?{~NFjkK. 8]3&SJVii1OMZ1PXDy fCh!t10b[99CpZ#z..{h1m^lcki,8GMk5G:56f$v[2e%5-d0}agGlM=,/5 8Eqv!#ueWD4:WA;:a`zCI9Nv !D3Z+T^ck+js=G8cjr 9Gj$3;Fxp_UHdQtWz Ku*03Ags_s99N|KhDaMs=fvnQhu8 &,WgM7gy%bybwOB.!o8WdY d!NMXn/]jk{x>+H#C}Dg,0~j]]fT& eH$-IC +*'_oXmW RSaf1Cu5h7+20N+|Qh__<>s!w!yoGg >Rl/8xa)^:/S-]cM4gQ`$,av|vv@=_mgGmr!>7w E9laU='y{suVC7=-?j:rt3sZ]xw?f'2Hs9"whv_?|T^$"x2u9Pao7`Ux#73h|NouY<9Yf0PRz+4Ay+slxO{[<}DC{j|XeMkp+V]f$r~>o{"GzF=_i3g]gGE'k=7mOto[%z[}t.n R`Zzbc:KC/@%{nv0Sv>87<3/yX## pt {}MX/i_~WPa~nFas&7Rm2`j?|Iu/_?#J__]u,eER? `nKmoG.#s6_^n)kh%lV%}Iv0,c2.C!^.m1z^ #Q'/2&=bx)B f~ KJmC=oTi$b&CE-GH1r}J=zGD@p+!T(RPo;2x{[&X9FU;^qB1L0 v~?RJ.oE.9m|}KBZ, hwWuF5xO7U b5hy?CSatGA4H}NU'2gah7NTa# 7MHDN$!LsC2_f4fT0xD_iLHVrA(. v%?D<6Y3r '6h ' dYCR* y5G+2Mk+Vl} 5|(TGz(Ca}wy)j}Znda.Fs`fyPlry9i_Lp]5|XZKH-{W(UA] 9bcEj:Ri>fq/MwR@+u6Rj<{f PyiQ K x1S{Nta;$`)dFPB?k9F[K$ MXwQE o{@R7SRFeT{E_Y5j1c|.T';XaJup 7Lr-Taaft 0X!oapT=RWL% P!uy2 k-lR?P/f-`wFso-}/)Pa.8~Y!j,I[OASI+1,puH_U(6 OYo6/EN1ibmD[iQ x_;'N]X1H"wi4T#)&W["6%+Kizrf8D)

More here:
Florida higher education official said women may earn less than men because of genetics - New York Daily News

Did That Fox Just Wag Its Tail? Inside a Bold Genetics Experiment – Undark Magazine

One spring morning in 1963, a Soviet scientist named Lyudmila Trut was making the rounds at a commercial fox farm, visiting several litters of three-week-old fox pups. As she approached one cage, a fuzzy male pup named Ember began to wag his tail. This simple, back-and-forth movement was a startling sight. Several years earlier, Trut and another scientist had launched an audacious experiment to solve the mysteries surrounding dog domestication by trying to replicate the process in foxes. Embers restless tail was the best sign yet that they were succeeding.

BOOK REVIEW How to Tame a Fox (and Build a Dog): Visionary Scientists and a Siberian Tale of Jump-Started Evolution, by Lee Alan DugatkinandLyudmila Trut (University of Chicago, 240 pages).

A six-decade project that challenged conventional wisdom about domestication and evolution and is still yielding new scientific insights.

Wagging their tails in response to humans is one of the signature behaviors of dogs, and until that day, they were the only animals observed to do so, Trut and the biologist Lee Alan Dugatkin write in their new book, How to Tame a Fox (and Build a Dog). And yet, here was Ember, who appeared to be wagging his tail due to a new emotional response to people, and if other pups also began to do so, that might prove to be a big step in the process of domestication. This comprehensive book provides an inside look at one of the most remarkable and longest-running experiments in science. Its a rich and fascinating story of a six-decade project that challenged conventional wisdom about domestication and evolution and is still yielding new scientific insights today.

The fox experiment was the brainchild of Dmitri Belyaev, a geneticist who worked at Moscows Central Research Laboratory on Fur Breeding Animals, where he was tasked with helping fox breeders produce animals that would earn more money for the Soviet Unions lucrative fur industry. But as he worked with the often-ferocious foxes that lived on Soviet fur farms, he began to wonder how humans had managed to tame the wolf a close relative of the fox into the docile domestic dog. Fossil evidence provided snapshots of how wild animals had changed over the course of domestication, but a major riddle remained unsolved: How had the process begun in the first place? As Dugatkin and Trut put it, How had fierce wild animals, intensely averse to human contact, become docile enough for our human ancestors to have started breeding them?

Belyaev had a theory. In his own work, he had noticed that while most foxes were aggressive or agitated around people, a few seemed to have an innate calmness. Perhaps, he speculated, all our ancestors had done was breed the wild wolves that seemed to be the most naturally docile, exhibiting the least fear of and aggression toward humans. And over evolutionary time, as our early ancestors had begun raising them and selecting for this innate tameness, the animals became more and more docile, Dugatkin and Trut write. He thought that all of the other changes involved in domestication had been triggered by this change in the behavioral selection pressure for tameness.

Belyaev decided to test his theory by putting it into action. He would start with wild foxes, breeding the tamest ones he could find over the course of many generations. If he could basically turn a fox into a dog-like animal, he might solve the longstanding riddle of how domestication comes about, the authors write.

The idea wasnt just scientifically bold it was politically risky. Stalins government had banned genetics research in 1948, calling it a bourgeois perversion, and many leading geneticists had been fired, arrested, imprisoned, and even executed. (Belyaevs older brother, a prominent geneticist, was among those killed.) So Belyaev would have to be discreet about the real purpose of his experiment, spinning it as physiological, rather than genetic, research.

In 1958, he recruited Trut, a young animal behaviorist, to run the experiment. She almost immediately began to have doubts about the endeavor. Having had no prior experience with foxes, Lyudmila was taken aback at first by how aggressive they were, Dugatkin and Trut write. Becoming acquainted with these fire-breathing dragons, as she called them, snarling and lunging at her when she approached their cages, she found it hard to believe that they could ever be tamed. Still, she would try. Each morning, she donned a pair of thick gloves and began visiting each fox, carefully observing its reaction as she approached, opened its cage, and slid a stick inside. She selected the calmest foxes, bred them together, and then selected the tamest of the pups to parent the next generation.

It didnt take long for dog-like traits to emerge. By the fourth generation and just the fourth year of the experiment Ember was wagging his tail. By the sixth, about 2 percent of the pups would lick Truts hand, roll over for belly rubs, and cry when their human caretakers walked away. By the following generation, 10 percent of the pups were displaying these behaviors. There seemed to be no doubt at all that these pups, from as early as they could walk, eagerly sought contact with humans, Dugatkin and Trut write. These tame foxes also seemed to have extended puppyhoods, remaining playful and curious well past the age that wild fox pups typically mature. Their bodies changed, too; the tame foxes developed curly tails, floppy ears, and piebald coats.

Maybe it wasnt the foxes underlying genetic code that was changing, but how the genes were regulated or expressed. The idea was wildly ahead of its time.

These new traits had appeared mind-bogglingly fast, over far fewer years and generations than evolution was thought to occur. The speed and nature of the changes led Belyaev to propose a radical theory. Belyaev had realized that most of the changes theyd seen in the foxes involved changes in the timing of when traits turn on and off, Dugatkin and Trut write. Many of the changes they were observing in the tamer foxes involved retaining a juvenile trait longer than normal. The whimpering was a youthful behavior that normally stopped as foxes matured. So was calmness; fox pups are serenely calm when theyre first born, but as they age, foxes typically become quite high-strung. It occurred to Belyaev that maybe it wasnt the foxes underlying genetic code that was changing from one generation to the next, but how the animals genes were regulated or expressed; certain genes that were already present in wild foxes might have become more or less active in the tame ones, or have turned on or off at different stages of development.

The idea was wildly ahead of its time, and it would be decades before research would bear it out. In the meantime, Belyaev and Trut kept breeding foxes. They built their own experimental fox farm in Siberia, and Trut moved into a nearby house with some of the tamest foxes, which quickly adopted behaviors common in pet dogs. (A visiting researcher later demonstrated that the tame foxes had the same high level of social intelligence that dogs did and better social cognition than the wild foxes.) Belyaev died in 1985, but two decades later, researchers finally validated his hypothesis, documenting differences in gene expression between tame and wild or aggressive foxes. (Gene expression isnt the entire story researchers have also found changes in gene sequence in the tame foxes but its clearly an important part of it.)

Dugatkin and Trut deftly synthesize scientific findings from fields ranging from genetics to animal cognition and openly grapple with some provocative unanswered questions: How much further can scientists push these foxes? What do the foxes tell us about the domestication of more distant species, such as cows and pigs? And might they teach us something about our own evolution? (Belyaev proposed that as we organized ourselves into ever-larger social groups, there would have been a selective advantage for individuals who were calm and comfortable around others, rather than aggressive and fearful. Essentially, we are domesticated, but in our case self-domesticated, primates, Dugatkin and Trut write.) The answers to these questions wont come easy, but the experiment is still running; considering what scientists have learned so far, theres no telling what evolutionary insights might emerge if they keep Belyaevs legacy and his line of tame foxes alive for another 60 years.

Emily Anthes, who has written for Undark, The New York Times, The New Yorker, Wired, and Scientific American, among other publications, is the author of Frankensteins Cat: Cuddling Up to Biotechs Brave New Beasts.

Go here to see the original:
Did That Fox Just Wag Its Tail? Inside a Bold Genetics Experiment - Undark Magazine

‘Genetics’ comment leads to calls for board member’s resignation … – NBC2 News

A member of the Governing Board of the State University apologized after suggesting the reason women make less than men is because of genetics.

But the National Organization for Women says the apology doesnt go far enough.

While discussing the pay gap between men and women graduates, Board of Governors member Ed Morton said: The women are given, maybe some of it is genetic, I dont know. Im not smart enough to know the difference.

A furor followed.

Governor Rick Scott, who appointed Morton, made it clear he didnt agree and released a statement through his press secretary saying, "As a father of two daughters, the Governor absolutely does not agree with this statement."

The following day, Morton apologized in a statement that said in part, I chose my words poorly. My belief is that women and men should be valued equally in the workplace.

The apology isnt enough for the National Organization for Women.

Mr. Morton should resign, said Barbara DeVane, a Lobbyist for Florida NOW.

NOW says if Morton doesnt step down, Rick Scott should remove him from office.

No one in 2017 should ever be making such a statement. Especially someone whos on the Board of Governors, DeVane said.

Florida is one of 15 states that has not ratified the Equal Rights Amendment.

Every session we dont even get a hearing, just like this past session. So for someone in this position to be making such a statement is idiotic and ignorant, she said. Genetics has nothing to do with the difference in salary between a man and a woman. It all has to do with discrimination.

In Florida, women who graduate from state universities are being paid on average $5,500 less each year than men.

Scotts press office failed to issue a statement regarding whether or not the governor would consider removing Morton from office in time for this story.

See the original post:
'Genetics' comment leads to calls for board member's resignation ... - NBC2 News

FSU boardmember suggests women’s salaries may be lower due to genetics – WFLA

TALLAHASSEE, Fla. (CAPITOL NEWS SERVICE) A member of the Florida State University Board of Governors is in hot water, after making a comment at board meeting in which he seemed to suggest differences in starting salaries between men and women maybe genetic and not cultural.

The comment spurred a backlash.

Floridas Board of Governors was told that statistics show women graduates make less than their male counterparts a year after leaving school.

Board member Ed Morton suggested teaching salary negotiating skills for women, but also said the gap may be genetic. The women are given, maybe some of its genetic, I dont know. Im not smart enough to know the difference, he said.

Morton, who was appointed by Governor Rick Scott, was quickly condemned by the Governor in a statement issued by his press secretary.

As a father of two daughters, the Governor absolutely does not agree with this statement.

Morton has since apologized, issuing a statement, but refusing interviews. He says in part I chose my words poorly. My belief is that women and men should be valued equally in the workplace.

The controversy comes after legislation failed in the 2017 regular session that attempted to close the wage gap between men and women.

More women than men graduate from Florida universities, still womens median starting salaries are $5,500 less than men, said Jake Stofen.

Dr. Wayne Hochwarter a professorof Organizational Behavior at FSU says the gap is more likely a result of women choosing professions that pay less.

Whereas you still have a large section of young men who are also in the business school and engineering, he said.

Hockwarter also says research shows women often times are better prepared and better equipped for situations like negotiating salaries.

STORIES OTHERS ARE CLICKING ON:

See the original post here:
FSU boardmember suggests women's salaries may be lower due to genetics - WFLA

Here’s How A Duke Professor Broke Down Wizard Genetics In ‘Harry … – HuffPost

Anyone who has sat through a high school biology lecture on genetics understands the basics of dominant and recessive alleles, which explain, among other things, how two brown-eyed parents can have a blue-eyed baby.

When you start talking magical ability, however, things become more complicated.

That was the topic of one panel at Future Con, a conventionwhere science meets science fiction, held this past weekend. In Harry Potter and the Genetics of Wizarding, Duke University professor Eric Spana discussed the intricacies of wizard DNA.

Fans of Harry Potter know that, while two magical parents will likely have magical children, thats not always the case. Occasionally, an all-magic union will result in a squib, or non-magic, child (think of poor Argus Filch, tasked with cleaning all of Hogwarts without so much as a wand to help him out). On the flip side, Hermione Granger one of the finest witches of all time, IMO was born to two muggle parents. Throughout the series, we learn that students like Seamus Finnigan had one magical and one muggle parent. So how the heck is magical ability passed on?

According to a summary of the panel from Live Science, Spana debated whether magical ability was a recessive trait (much like the Weasley familys red hair), meaning its possible for an individual to carry the gene and potentially pass that gene onto offspring without expressing its traits. He ultimately decided it wasnt, though thanks to one Rubeus Hagrid.

You see, Hagrid was born to a giant mother and a wizard father. This meant Hagrid was born a wizard with only one copy of wizarding DNA in his blood (giants are non-magical). Thus, Spana concluded, magical ability must be a dominant trait.

If thats the case, how did Spana explain children like Hermione, who are the first in her family line with magical powers? A good, old-fashioned genetic mutation, possibly occurring in a sperm or egg cell, or after the egg is fertilized. (Yeah, dont you wish youd remembered more from AP Biology now?) As for squibs, Spana posited that parents could carry a mutation of the wizarding gene and pass it on to their child.

Science, man. Its pretty magical.

From June 1 to 30, HuffPost is celebrating the 20th anniversary of the very first Harry Potter book by reminiscing about all things Hogwarts. Accio childhood memories.

See the original post here:
Here's How A Duke Professor Broke Down Wizard Genetics In 'Harry ... - HuffPost

Myriad Genetics: Worth A Bet On Diagnostics Kit Pricing Expansion? – Seeking Alpha

I generally avoid the biotech/health tech space, but the Myriad Genetics (NASDAQ:MYGN) story is simple enough to understand and evaluate. After riding high for years, the company came under pressure within its core competency: hereditary cancer diagnostics. Diversification and M&A efforts have proven to not be enough to stem the tide of margin erosion from fresh competition, and within a beaten-down sector that values growth highly, it shouldn't be a surprise that the shares have seen their value cut in half over the past two years. 2017 has been a year of recovery for shares, particularly over the last two months. As a fan of the company's business model and story, I'm glad to see it finally building a base. As an investor, however, the question remains simple: Does Myriad Genetics have long-term value potential, and is now the time to buy?

Business Overview, Long-Term Outlook

Founded in 1991 and based out of Salt Lake City, Myriad Genetics focuses on the development and marketing of predictive prognostic medicine tests. Diagnostics the company provides allow the assessment of an individual's risk for developing a disease, identifying the likelihood a patient will respond to certain drug therapies, the risk of recurrence/rate of progression, or providing guidelines for dosing. As a staunch critic of how the United States healthcare system is run, any company that helps to drive down overall costs via the elimination of misdiagnosis and improving early detection, all while improving patient welfare, is going to tend to be in my good graces.

Tests include, but are not limited to, BRACAnalysis and BART (hereditary breast and ovarian cancers), COLARIS (colorectal/uterine cancers), and myPath Melanoma (RNA expression test for melanoma). Overall, Myriad targets six medical specialties: oncology, dermatology, autoimmune, urology, neuroscience, and preventive care. According to the company (as sourced from Clinical Lab Products magazine), diagnostic tests represent just 3% of overall healthcare spending domestically but drive 70% of healthcare decision-making. Figures vary depending on where you look, but overall consensus is that there's hundreds of billions of dollars in wasteful spending in the United States health market, and proper testing and diagnostics could help eliminate a meaningful percentage of that waste.

Strategically, the company wants to hit double-digit revenue growth and improve the international revenue base, all while maintaining a better than 30% operating margin. That's a tall order, particularly given that hereditary cancer revenue, the company's core competency, has been tailing off since fiscal year 2014. While Myriad Genetics does likely have some differentiation due to first-mover advantage (twenty years of experience, nearly 3M patients tested, has identified tens of thousands of variants), the problem keeps coming down to average selling prices ("ASPs"). In the most recent quarter, for instance (Q3 of fiscal 2017), Myriad Genetics grew hereditary cancer testing volumes in a tough quarter seasonally for the first time in five years. Great, right? The problem was hereditary cancer revenue fell 10% y/y, an acceleration from the drop from the 2015/2016 comp drop. The entire decline is therefore attributable to pricing; management also points to revenue recognition delays from an Anthem (NYSE:ANTM) out-of-network decision as well, which is set to continue into the next quarter.

As goes hereditary cancer products, so does consolidated revenue. Revenue was up 3% in fiscal Q3 2017, but only due to the acquisition of GeneSight products ($24 million in revenue contribution), which were added based on the August 2016 acquisition of Assurex Health ($225 million in cash, potential for $185 million in additional payments based on performance milestones). Growth has been great there, with revenues up 44% y/y (7% sequentially). A product from another key acquisition, Vectra DA (acquired from Crescendo Bioscience for $245 million in cash), unfortunately posted y/y declines (9%). However, this quarter marked a return to sequential growth after the company clarified some issues relating to a study with negative results. That ties into the ongoing situation with Medicare non-coverage, but Myriad Genetics is optimistic that there will be a favorable resolution. Supporting data is on the way, with the company recently announcing the completion of enrollment in a 1,200-person clinical study which will provide data within calendar year 2017. Prolaris posted revenue declines, mostly due to a Medicare retrospective payments unfavorable comp last year. Volumes were up, breaching the 20,000 annual run rate for the first time. The comment period on the Medicare Favorable Intermediate LCD concluded recently, and if Medicare confirms, it will expand reimbursement coverage by 50%.

While there are negatives here (namely, volume growth at the expense of ASPs), Myriad spins these business lines as having serious potential, primarily due to higher ASP outlook. The majority of these products have issues with insurance non-coverage, which drives down ASPs to cash-paying customers that want access, as well as denting volume. Driving greater commercial insurance adoption is a key goal, and one that is central to the underlying investment thesis. If Myriad Genetics cannot prove out that its products can save insurance companies significantly - by the company's estimates hundreds of millions per year for large payers - then it is going to struggle.

There are nearly a dozen clinical studies that will conclude over the next two years that could boost visibility of the company's products, particularly in metastatic breast, ovarian, and pancreatic cancers, which could lead to adoption. With that said, I am not convinced that ASPs will see the rise management is expecting. A lot of existing large payer contracts within hereditary have seen pricing concessions in order to lock in longer deals, and I suspect there might be more pressure on pricing than expected. However, non-hereditary products do make up 68% of volume but only 28% of revenue. There is plenty of opportunity for expansion there, at least compared to hereditary as a baseline.

This is a likely reason why there is a strong focus on international sales. The European Union and Canada tend to be much quicker at adopting new technologies in the medical space, although pricing is often much lower than the United States. Expect Prolaris, Vectra DA, EndoPredict, and the various myPlan hereditary platforms to be pushed overseas. The international mix has picked up quite a bit since fiscal 2014 (<1% revenue) to 5% today, and I think it is a more than reasonable expectation that Myriad Genetics reaches its goal of 10% of revenue being sourced internationally by the end of fiscal 2020.

Roadmap To 2020, Valuation

For shareholders, growth of non-hereditary, both in volume and price, is paramount to a long thesis. Myriad Genetics has a goal of $1,200 million in revenue by fiscal 2020, but it also sees $300 million in run-off of revenue from hereditary, or basically a 50% haircut from current levels. To fill the gap, management is looking for 15% annual growth from the company's so-called stage three products (GeneSight, Vectra DA, Prolaris, EndoPredict), with considerably less emphasis on products not as far along in development. But importantly, the company bases this on 75% reimbursement, which requires significant increases in average selling prices:

*Myriad Genetics, 2017 Investor Presentation

Investors clearly believe in a turnaround; Myriad Genetics is now more expensive on trailing measures (EV/EBITDA, P/E) than it has been for most of its recent history. However, there is a lot of upside if the company can execute; fiscal 2020 would see EBITDA in the $430 million range based on management targets, enough to warrant the shares more than doubling in value (EV to $3,870 million on a 9x multiple, 132%). This is a story of execution and a little bit of faith in whether CEO Mark Capone and team are both setting realistic goals and have the clout to achieve them. Unfortunately, my expertise ends there, and I have no way of assigning a fair probability to achieving those goals. I've got to take a pass on the company as a result, but I can see why many investors are interested, particularly after the recent fall.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The rest is here:
Myriad Genetics: Worth A Bet On Diagnostics Kit Pricing Expansion? - Seeking Alpha

A Florida higher-ed official said women’s genetics may be keeping them from equal pay – Washington Post

A Florida college official said Tuesday that women make less money than men because genetically they might lack the skills to negotiate for better pay.

Edward Morton ofthe State University System of Florida made the comments during a board meeting in which members talked about closing the wage gap between male and femalegraduates of the states public university system.Morton, chair of the boards Strategic Planning Committee and a financial adviser from Naples, Fla., said,according to Politico:

Something that were doing in Naples some of our high school students, were actually talking about incorporating negotiating and negotiating skill into curriculum so that the women are given maybe some of it is genetic, I dont know, Im not smart enough to know the difference but I do know that negotiating skills can be something that can be honed, and they can improve. Perhaps we can address than in all of our various curriculums through the introduction of negotiating skill, and maybe that would have a bearing on these things.

Morton apologized for his comment in an email sent to fellow board members shortly after the meeting.

I chose my words poorly. My belief is that women and men should be valued equally in the workplace, he said, adding that the universitys goal is to teach all students how to better negotiate their salaries.

[Utah Republican argues against equal pay for women: Its bad for families and society]

Gov. Rick Scott, who appointed Morton to the board, was among those who quickly criticized Morton for hiscomments. Lauren Schenone, a spokeswoman for Scott, said in a statement that as a father of two daughters, the governorabsolutely does not agree with Mortonscomments.

Gwen Graham, whos seeking the Democratic nomination for governor,tweeted Tuesday night:When I sat at the negotiation table, nothing about my gender or genetics held me back. THIS is why we need more women in state government.

Morton did not return a call seeking comment Wednesday.

Politico reported that during the meeting board members were reviewing areport on gender wage gaps among students who graduated from the university system in 2015.The report, which looked at what students did after graduation and how much theyre earning, found that female graduates from various fieldshave an annual median salary of $37,000, which is $5,500 less than the median salary of male graduates. African American graduates make even less, with an annual median wage of $35,600.

[Here are the facts behind that 79 cent pay gap factoid]

Femalegraduates make less than men even though they account fornearly 60 percent of the graduating class, according to the report.Blacks, Hispanics and whites make up 12 percent, 25 percent and 52 percent of the graduating class, respectively.

During the meeting, Morton said that the wage gap will in some way be self-correcting because the university system has more female graduates than men, according to Politico.

The report also found significant discrepancies in pay among men and women who graduated with the same degrees.The median salaries of women with degrees in biological sciences, business and marketing, communication and journalism, security and protective services, social sciences, and visual and performing arts are from$1,200to $4,400 lower than those of men with similar credentials.The gap among agriculture, liberal arts and physical sciences graduates is even greater from $6,400to $9,400.

Yet the report also found that women with degrees in education, engineering, health professions and psychology make from$500 to$3,100 more than their male counterparts annually.

A history of the long fight for gender wage equality. (Daron Taylor/The Washington Post)

Florida is among more than a dozen states with equal pay laws that haveloopholes that allow employers to continue to pay women less, according to the American Association of University Women.Two states, Alabama and Mississippi, have no equal paylaws. And only a handful California, Illinois, Minnesota, Vermont, Massachusetts and Maryland have strong equal pay laws.

Nationally, womens annual earnings are about 80 percent of what men make, according to a recent report by the association.

The report attributes the wage gap partly to differences in career choices and to the fact that parenting more often puts womens professional lives at a disadvantage than it does mens. Twenty-three percent of mothers left the workforce 10 years after graduation, while 17 percent worked part-time, according to the association. Those numbers among fathers were 1 percent and 2 percent, respectively.

Despite factors such as life choices and parenting, women facepay gaps at every education level and in nearly every line of work, the report said.

READ MORE:

In the federal government, how likely is it that a woman will make more than a man?

The poor just dont want health care: Republican congressman faces backlash over comments

Nobody dies because they dont have access to health care, GOP lawmaker says. He got booed.

Continued here:
A Florida higher-ed official said women's genetics may be keeping them from equal pay - Washington Post

Accelerated Genetics may expand operations under new ownership – La Crosse Tribune

Accelerated Genetics in Westby may expand its operation following a potential merger.

Angie Lindloff, vice president of marketing and communications, said staff downsizing isnt likely to occur even if Accelerated Genetics is sold to the larger, Ohio-based Select Sires. It was recently announced the two companies, which specialize in artificial insemination of cattle, may combine forces.

Lindloff said that while there are no guarantees of job security, Westby employees could see more bulls in housing than before. She said Select Sires aims to increase local production for international markets.

My understanding is (Select Sires) wants to keep the Westby facility intact and the people intact, Lindloff said. The goal is, they want that facility to maximize production out of it. Its actually a good thing from a Westby standpoint.

Roughly 70 people work for Accelerated Genetics in Westby, Lindloff said. The municipality is home to multiple Accelerated Genetics production barns, an office and a distribution center.

Select Sires, theyre very interested in the assets at Westby and the people there, Lindloff said. They know what we do there and they understand we have a lot of valuable people.

The Accelerated Genetics production facility houses more than 200 bulls, staff veterinarian Katie Speller said. Speller said the bulls supply genes for Accelerated Genetics national and international markets, including in Europe, Asia, Africa and the Middle East.

Following a potential merger with Select Sires, Lindloff said the company could move to increase Westbys international production capabilities and bring in more cattle.

She said that barns producing semen for the European Union require special permitting, and Select Sires would aim to uptick the number of EU-certified barns in Westby.

Select Sires and Accelerated Genetics have an established business relationship. In 2001, the two companies began collaborative marketing efforts in foreign markets.

Select Sires is now poised to take over Accelerated Genetics, which has struggled financially.

We have been looking at something like this, something different than our current model, because we knew it was getting harder to do business, Lindloff said of Accelerated Genetics. So if we combine forces with somebody, it gives us more resources and just more opportunities to grow together.

Accelerated Genetics operates as a cooperative with member farms in Minnesota, Iowa, Wisconsin and Illinois. Under the potential acquisition, Accelerated Genetics member farms in those states would be rolled into one of Select Sires existing cooperatives.

Select Sires operates across the U.S.

Delegates from Accelerated Genetics are scheduled to cast final votes on the merger later this month. Select Sires did not return a phone call seeking comment by press time.

Read the rest here:
Accelerated Genetics may expand operations under new ownership - La Crosse Tribune

Genetics Pioneer Craig Venter and Exxon Claim Algae Biofuel Breakthough (Again) – Greentech Media

Every few years, J. Craig Venter of Synthetic Genomics and Exxon issue a joint proclamation about progress in biofuels derived from algae. Venter gets funded, Exxon gets green cred, breathless articles get written in the business press, and we are once again reminded that algae is the fuel of the future.

Venter has made brilliant contributions to modern genetics. He was part of the team that sequenced the second human genome.

Still, the team of Exxon and Synthetic Genomics have been working on algal biofuels since 2009, and although they are claiming a biofuel "breakthrough" in their latest release, the time frame for commercialization verges on generational as opposed to the decade-scale promises that have been made. Exxon called this a $600 million investment in 2009.

According to the most recent release, the partners have developed an algal strain that has "more than doubled its oil content without significantly inhibiting the strains growth." The research team claims to have modified the algae speciesNannochloropsis gaditana to stretch the algaes oil content from 20 percent to more than 40 percent. (That 40 percent figure has been tossed around by other researchers in recent years, as well.)

The release is careful to stress that this is deep research and "a proof-of-concept approach." Despite the laudatory articles being written, we are not much closer to commercial biofuels derived from algae oil.

In 2009, current U.S. Secretary of State and former Exxon CEO Rex Tillerson said that the venture might not produce real results for another 25 years.

Were still at the research phase in this program, cautions Vijay Swarup, a vice president at ExxonMobil, as quoted in Forbes. Its not just doubling [lipid production], but its understanding why it doubled and how it doubled," he said. "Theres still a long way to go in making an algae that can produce even more fat, live comfortably in saltwater pools outside, and be processed into fuel for cars, planes and trains."

The release notes that an objective of the collaboration "has been to increase the lipid content of algae while decreasing the starch and protein components without inhibiting the algaes growth. Limiting availability of nutrients such as nitrogen is one way to increase oil production in algae, but it can also dramatically inhibit or even stop photosynthesis, stunting algae growth and ultimately the volume of oil produced."

Bloomberg notes that the team "searched for the needed genetic regulators after observing what happened when cells were starved of nitrogen -- a tactic that generally drives more oil accumulation. Using the CRISPR-Cas9 gene-editing technique, the researchers were able to winnow a list of about 20 candidates to a single regulator -- they call it ZnCys -- and then to modulate its expression."

As we've reported, from 2005 to 2012, dozens of companies managed to extract hundreds of millions in cash from VCs in hopes of ultimately extracting fuel oil from algae.

The promise of algae is tantalizing. Some algal species contain up to 40 percent lipids by weight, a figure that could be boosted further through selective breeding and genetic modification. That basic lipid can be converted into diesel, synthetic petroleum, butanol or industrial chemicals.

Today, most of the few surviving algae companies have had no choice but to adopt new business plans that focus on the more expensive algae byproducts such as cosmetic supplements, nutraceuticals, pet food additives, animal feed, pigments and specialty oils. The rest have gone bankrupt or moved on to other markets.

The Exxon-SGI partnership is one of the few remaining algae biofuel efforts.

According to some sources, an acre of algae could yield 5,000 to 10,000 gallons of oil a year, making algae far more productive than soy (50 gallons per acre), rapeseed (110 to 145 gallons), jatropha (175 gallons), palm (650 gallons), or cellulosic ethanol from poplars (2,700 gallons).

The question remains: Can algae be economically cultivated and commercially scaled to make a material contribution to humanity's liquid fuel needs? Can biofuels from algae compete on price with fossil-derived petroleum?

Once capital needs, water availability, energy balance, growing, collecting, drying, and algae's pickiness about light and CO2 are factored in -- the answer, so far, is an emphatic no.

Here's a recently compiled list, by no means complete, of algae companies attempting to pivot away from biofuels.

There are many pieces to the algae puzzle that seem like afterthoughts, but which are actually crucial to the economics -- including co-products, nutrients, harvesting, drying and conversion technology. System design and algae type (which seem to be the focus of this and most discussions) are important, but not the only components.

Considering the immense technical risks and daunting capital costs of building an algae fuel company, it doesnt seem like a reasonable venture capital play. And most -- if not all -- of the VCs Ive spoken with categorize these investments as the longer-term, long-shot bets in their portfolio. But given the size of the liquid fuels market, measured in trillions of dollars, not the customary billions of dollars, it makes some sense to occasionally take the low-percentage shot.

Link:
Genetics Pioneer Craig Venter and Exxon Claim Algae Biofuel Breakthough (Again) - Greentech Media